Infinity Pharmaceuticals has gained access to Intellikine's portfolio of phosphoinositide 3-kinase-δ (PI3Kδ) and PI3Kγ inhibitors for inflammation and oncology indications through an exclusive ...

Data accumulated to date with respect to various PI3K inhibitors suggest improved response rates and longer survival compared with existing therapeutic options. Longer-term follow-up is essential ...

Addition of the PI3K inhibitor inavolisib to palbociclib–fulvestrant might improve outcomes. New research findings are summarized in a short video.

HOUSTON -- Two-thirds of patients with PI3K -mutant brain metastases responded to the maximum tolerated dose (MTD) of the ...

该研究表明，使用特定的抑制剂（如AZD4573）靶向CDK9可以显著损害palbociclib敏感性和耐药的LTED细胞系的活力，以及患者来源的类器官（PDO）和PDX模型。

Olema Oncology plans to start a Phase III trial studying palazestrant with a CDK4/6 inhibitor from Novartis in mid-2025.

We discovered and helped develop one of the very first in a new class of PI3 kinase inhibitors. The drug, known as pictilisib (previously GDC-0941), was discovered by the Cancer Research UK Cancer ...

Copanlisib is a pan-Class I phosphatidylinositol-3-kinase (PI3K) inhibitor with predominant inhibitory activity against PI3K-α and PI3K-δ isoforms, which the FDA will review in relapsed or ...

For patients with chronic lymphocytic leukemia (CLL) treated previously with venetoclax and Bruton’s tyrosine kinase ...